Loading
FTO (Alpha-ketoglutarate-dependent dioxygenase FTO) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
RNA demethylase that mediates oxidative demethylation of different RNA species, such as mRNAs, tRNAs and snRNAs, and acts as a regulator of fat mass, adipogenesis and energy homeostasis. Specifically demethylates N(6)-methyladenosine (m6A) RNA, the most prevalent internal modification of messenger RNA (mRNA) in higher eukaryotes. M6A demethylation by FTO affects mRNA expression and stability.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 1.00, genetic association 0.77, clinical 0.16).
In plain words · FTO (Alpha-ketoglutarate-dependent dioxygenase FTO) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
FTO (Alpha-ketoglutarate-dependent dioxygenase FTO) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
RNA demethylase that mediates oxidative demethylation of different RNA species, such as mRNAs, tRNAs and snRNAs, and acts as a regulator of fat mass, adipogenesis and energy homeostasis.
No product in this corpus aims at FTO yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA FTO: RNA low tissue specificity; high antibody staining in 13 normal tissues; highest cancer staining renal cancer (5 of 11 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Breast cancer (all types)); Open Targets associates it with 3 specific cancer types at or above 0.5 (breast carcinoma, breast cancer, triple-negative breast carcinoma); the corpus evidence decides and the Open Targets list is quoted for comparison. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas FTO tissue; Open Targets ENSG00000140718 associations
First described 2000. Earliest sequence paper UniProt cites for the protein: Nagase et al, DNA Res, 2000, "Prediction of the coding sequences of unidentified human genes. XIX. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro". Source.
Sources: HGNC HGNC:24678 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9C0B1 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000140718 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: breast cancer 0.61 (GraphQL API, CC0))
RNA demethylase that mediates oxidative demethylation of different RNA species, such as mRNAs, tRNAs and snRNAs, and acts as a regulator of fat mass, adipogenesis and energy homeostasis. Specifically demethylates N(6)-methyladenosine (m6A) RNA, the most prevalent internal modification of messenger RNA (mRNA) in higher eukaryotes. M6A demethylation by FTO affects mRNA expression and stability. Also able to demethylate m6A in U6 small nuclear RNA (snRNA). Mediates demethylation of N(6),2'-O-dimethyladenosine cap (m6A(m)), by demethylating the N(6)-methyladenosine at the second transcribed position of mRNAs and U6 snRNA. Demethylation of m6A(m) in the 5'-cap by FTO affects mRNA stability by promoting susceptibility to decapping. Location: Nucleus; Nucleus speckle; Cytoplasm (UniProt). Locus 16q12.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Appendix, Breast, Bronchus, Caudate, Cerebral cortex, Endometrium, Esophagus, Fallopian tube.
Medium only: breast cancer, carcinoid, cervical cancer, endometrial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FTO" OR ABSTRACT:"FTO" OR TITLE:"FTO alpha-ketoglutarate dependent dioxygenase" OR ABSTRACT:"FTO alpha-ketoglutarate dependent dioxygenase" OR TITLE:"Alpha-ketoglutarate-dependent dioxygenase FTO" OR ABSTRACT:"Alpha-ketoglutarate-dependent dioxygenase FTO" OR TITLE:"KIAA1752" OR ABSTRACT:"KIAA1752" OR TITLE:"MGC5149" OR ABSTRACT:"MGC5149" OR TITLE:"ALKBH9" OR ABSTRACT:"ALKBH9") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FTO, not a curated reading list.